首页 > 最新文献

JAMA dermatology最新文献

英文 中文
Outcomes of Importance to Patients Living With Cutaneous Chronic Graft-vs-Host Disease.
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-01-02 DOI: 10.1001/jamadermatol.2024.5380
Emily Baumrin, Peter F Cronholm, Matthew D Kearney, Mlka Mengesha, Laura G Cesar, Shimrit Keddem, Marilyn M Schapira, Stephanie J Lee, Alison W Loren, Joel M Gelfand

Importance: Cutaneous chronic graft-vs-host disease (GVHD) is independently associated with morbidity and mortality after allogeneic hematopoietic cell transplant. However, the health-related quality-of-life (HRQOL) domains that are most important to patients are poorly understood.

Objective: To perform a concept elicitation study to define HRQOL in cutaneous chronic GVHD from the patient perspective and to compare experiences of patients with epidermal vs sclerotic disease.

Design, setting, and participants: A single-center qualitative analysis from open-ended, semistructured interviews and free-listing terms conducted between April and September 2023. Participants were 18 years or older with a diagnosis of active cutaneous chronic GVHD, purposefully sampled for epidermal and sclerotic disease features, with ongoing sampling until thematic saturation.

Main outcomes: HRQOL domains and codes from patient perspectives of living with cutaneous chronic GVHD were identified by inductive analysis of semistructured interviews. Smith salience index (Smith S) score, a measure of saliency for each list term, was calculated from free-listing terms from deidentified patient interviews.

Results: A total of 31 adults with cutaneous chronic GVHD (median [IQR] age, 61.1 [52.9-68.7] years) participated in interviews; 17 participants (54.8%) were male and 14 (45.2%) were female. Nine participants (29.0%) had epidermal, 13 (41.9%) sclerotic, and 9 (29.0%) a combination of disease types. The study identified 40 codes of importance grouped within 5 HRQOL domains: skin changes and symptoms, social functioning, psychological and emotional functioning, physical functioning, and general health perceptions. The most frequent symptoms were dry skin (n = 20 [65%]), tight skin (n = 19 [61%]), itch (n = 15 [48%]), and discoloration (n = 14 [45%]), which were seen in all disease subtypes. Impairment in social functioning was noted by all participants. Psychological and emotional functioning, including frustration (Smith S score, 0.32) and worry or concern (Smith S score, 0.12), and symptoms including discomfort (Smith S score, 0.20) were the most salient to patients. Individual and environmental factors, such as social comparison, illness comparison with cancer, anatomic location of disease involvement, and disease duration, affected the relationship between skin changes and symptoms and downstream functioning and general health perceptions.

Conclusions and relevance: This qualitative analysis demonstrated the direct relationship between cutaneous chronic GVHD and HRQOL domains and identified codes not represented in existing GVHD- and dermatology-specific patient-reported outcome measures. These results can guide patient-reported outcome development and instrument selection for clinical trials and improve clinical decision-making.

{"title":"Outcomes of Importance to Patients Living With Cutaneous Chronic Graft-vs-Host Disease.","authors":"Emily Baumrin, Peter F Cronholm, Matthew D Kearney, Mlka Mengesha, Laura G Cesar, Shimrit Keddem, Marilyn M Schapira, Stephanie J Lee, Alison W Loren, Joel M Gelfand","doi":"10.1001/jamadermatol.2024.5380","DOIUrl":"https://doi.org/10.1001/jamadermatol.2024.5380","url":null,"abstract":"<p><strong>Importance: </strong>Cutaneous chronic graft-vs-host disease (GVHD) is independently associated with morbidity and mortality after allogeneic hematopoietic cell transplant. However, the health-related quality-of-life (HRQOL) domains that are most important to patients are poorly understood.</p><p><strong>Objective: </strong>To perform a concept elicitation study to define HRQOL in cutaneous chronic GVHD from the patient perspective and to compare experiences of patients with epidermal vs sclerotic disease.</p><p><strong>Design, setting, and participants: </strong>A single-center qualitative analysis from open-ended, semistructured interviews and free-listing terms conducted between April and September 2023. Participants were 18 years or older with a diagnosis of active cutaneous chronic GVHD, purposefully sampled for epidermal and sclerotic disease features, with ongoing sampling until thematic saturation.</p><p><strong>Main outcomes: </strong>HRQOL domains and codes from patient perspectives of living with cutaneous chronic GVHD were identified by inductive analysis of semistructured interviews. Smith salience index (Smith S) score, a measure of saliency for each list term, was calculated from free-listing terms from deidentified patient interviews.</p><p><strong>Results: </strong>A total of 31 adults with cutaneous chronic GVHD (median [IQR] age, 61.1 [52.9-68.7] years) participated in interviews; 17 participants (54.8%) were male and 14 (45.2%) were female. Nine participants (29.0%) had epidermal, 13 (41.9%) sclerotic, and 9 (29.0%) a combination of disease types. The study identified 40 codes of importance grouped within 5 HRQOL domains: skin changes and symptoms, social functioning, psychological and emotional functioning, physical functioning, and general health perceptions. The most frequent symptoms were dry skin (n = 20 [65%]), tight skin (n = 19 [61%]), itch (n = 15 [48%]), and discoloration (n = 14 [45%]), which were seen in all disease subtypes. Impairment in social functioning was noted by all participants. Psychological and emotional functioning, including frustration (Smith S score, 0.32) and worry or concern (Smith S score, 0.12), and symptoms including discomfort (Smith S score, 0.20) were the most salient to patients. Individual and environmental factors, such as social comparison, illness comparison with cancer, anatomic location of disease involvement, and disease duration, affected the relationship between skin changes and symptoms and downstream functioning and general health perceptions.</p><p><strong>Conclusions and relevance: </strong>This qualitative analysis demonstrated the direct relationship between cutaneous chronic GVHD and HRQOL domains and identified codes not represented in existing GVHD- and dermatology-specific patient-reported outcome measures. These results can guide patient-reported outcome development and instrument selection for clinical trials and improve clinical decision-making.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sarcoidosis-Specific Cutaneous Lesion Distribution in Clinical Assessment for Cardiac Sarcoidosis.
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-01-02 DOI: 10.1001/jamadermatol.2024.5141
Michelle Sikora, Chinemelum Obijiofor, Angelo Osofsky, Lynn Liu, Soutrik Mandal, Kristen I Lo Sicco, Avrom S Caplan
{"title":"Sarcoidosis-Specific Cutaneous Lesion Distribution in Clinical Assessment for Cardiac Sarcoidosis.","authors":"Michelle Sikora, Chinemelum Obijiofor, Angelo Osofsky, Lynn Liu, Soutrik Mandal, Kristen I Lo Sicco, Avrom S Caplan","doi":"10.1001/jamadermatol.2024.5141","DOIUrl":"https://doi.org/10.1001/jamadermatol.2024.5141","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multi-Institutional Clinical Forensic Dermatology Training for Dermatology Residents.
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-01-02 DOI: 10.1001/jamadermatol.2024.5301
Maha Kazmi, Mehar Maju, Rubi Danielle Montejano, Ivan Rodriguez, Coleen Kivlahan, Herbert B Castillo Valladares
{"title":"Multi-Institutional Clinical Forensic Dermatology Training for Dermatology Residents.","authors":"Maha Kazmi, Mehar Maju, Rubi Danielle Montejano, Ivan Rodriguez, Coleen Kivlahan, Herbert B Castillo Valladares","doi":"10.1001/jamadermatol.2024.5301","DOIUrl":"https://doi.org/10.1001/jamadermatol.2024.5301","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychometric Properties and Meaningful Change Thresholds of the Vitiligo Area Scoring Index. 白癜风面积评分指数的心理特性和有意义变化阈值。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-01-01 DOI: 10.1001/jamadermatol.2024.4534
Khaled Ezzedine, Ahmed M Soliman, Heidi S Camp, Mary Kate Ladd, Robin Pokrzywinski, Karin S Coyne, Rohini Sen, Bethanee J Schlosser, Jung Min Bae, Iltefat Hamzavi
<p><strong>Importance: </strong>Defining meaningful improvement using the Total Vitiligo Area Scoring Index (T-VASI) and the Facial VASI (F-VASI) aids interpretation of findings from clinical trials evaluating vitiligo treatments; however, clear and clinically meaningful thresholds have not yet been established.</p><p><strong>Objective: </strong>To assess concept validity and measurement performance of the T-VASI and F-VASI in patients with nonsegmental vitiligo and to identify meaningful change thresholds.</p><p><strong>Design, settings, and participants: </strong>This mixed-methods study consisted of a secondary analysis of a phase 2 multicenter double-blind dose-ranging randomized clinical trial and embedded qualitative interviews conducted at 35 sites in Canada, France, Japan, and the US. The secondary analysis included the trial's adult patients with nonsegmental vitiligo (T-VASI ≥5 and F-VASI ≥0.5 at baseline). Psychometric performance of the T-VASI and F-VASI and thresholds for meaningful change were evaluated using clinician- and patient-reported information. The trial's embedded interviews were used to qualitatively assess content validity and patient perceptions of meaningful repigmentation. Data analyses were performed from March to July 2023.</p><p><strong>Intervention: </strong>Participants were randomized to 6-, 11-, or 22-mg/day upadacitinib or placebo for 24 weeks.</p><p><strong>Main outcomes and measures: </strong>Psychometric performance of the T-VASI and F-VASI and thresholds for meaningful changed plus content validity and patient perceptions of meaningful repigmentation. Measurement instruments included the T-VASI, F-VASI, Vitiligo Noticeability Scale, Total-Patient Global Vitiligo Assessment, Face-Patient Global Vitiligo Assessment, Total-Physician Global Vitiligo Assessment (PhGVA-T), Face-Physician Global Vitiligo Assessment (PhGVA-F), Patient's Global Impression of Change-Vitiligo, Physician's Global Impression of Change-Vitiligo (PhGIC-V), Vitiligo Quality-of-Life Instrument, Dermatology Life Quality Index, the Hospital Anxiety and Depression Scale, and transcribed verbatim interviews with patients.</p><p><strong>Results: </strong>The psychometric analysis included 164 participants (mean [SD] age, 46 years; 103 [63%] females) and the qualitative analysis included 14 participants (mean [SD] age, 48.8 [12.2] years; 9 females [64%] and 5 males [36%]). Intraclass correlation coefficients were 0.98 for T-VASI and 0.99 for F-VASI in patients with clinically stable vitiligo between baseline and week 4, supporting test-retest reliability. At baseline and week 24, correlations were moderate to strong between T-VASI and PhGVA-T (r = 0.63-0.65) and between F-VASI and PhGVA-F (r = 0.65-0.71). Average baseline and week-24 VASI scores decreased with repigmentation (ie, increasing PhGVA scores). Least-square mean VASI scores increased with greater repigmentation as measured by the PhGIC-V. Least-square mean VASI scores also differed be
重要性:使用白癜风面积总评分指数(T-VASI)和面部VASI(F-VASI)来定义有意义的改善有助于解释评估白癜风治疗方法的临床试验结果;然而,目前尚未确定明确且有临床意义的阈值:评估T-VASI和F-VASI在非节段性白癜风患者中的概念有效性和测量性能,并确定有意义的变化阈值:这项混合方法研究包括对一项第 2 期多中心双盲剂量范围随机临床试验的二次分析,以及在加拿大、法国、日本和美国 35 个地点进行的嵌入式定性访谈。二次分析包括试验中的非节段性白癜风成年患者(基线时T-VASI≥5,F-VASI≥0.5)。利用临床医生和患者报告的信息评估了T-VASI和F-VASI的心理测量性能以及有意义变化的阈值。试验的嵌入式访谈用于定性评估内容效度和患者对有意义再色素沉着的看法。数据分析于 2023 年 3 月至 7 月进行:参与者随机接受每天6、11或22毫克的达达替尼或安慰剂治疗,为期24周:主要结果:T-VASI和F-VASI的心理测量性能和有意义改变的阈值,以及内容效度和患者对有意义再色素沉着的看法。测量工具包括 T-VASI、F-VASI、白癜风可察觉性量表、患者整体白癜风评估、面部患者整体白癜风评估、医生整体白癜风评估 (PhGVA-T)、面部医生整体白癜风评估 (PhGVA-F)、患者对变化的总体印象--白癜风、医生对变化的总体印象--白癜风(PhGIC-V)、白癜风生活质量量表、皮肤科生活质量指数、医院焦虑和抑郁量表,以及对患者的逐字记录访谈。结果:心理测量分析包括 164 名参与者(平均 [SD] 年龄 46 岁;103 [63%] 名女性),定性分析包括 14 名参与者(平均 [SD] 年龄 48.8 [12.2] 岁;9 名女性 [64%] 和 5 名男性 [36%])。在基线和第4周之间,临床稳定期白癜风患者的T-VASI类内相关系数为0.98,F-VASI类内相关系数为0.99,证明了测试-复测的可靠性。在基线和第24周,T-VASI和PhGVA-T(r = 0.63-0.65)以及F-VASI和PhGVA-F(r = 0.65-0.71)之间存在中度到高度相关性。基线和第 24 周的平均 VASI 分数随着再色素沉着(即 PhGVA 分数增加)而降低。根据 PhGIC-V 测量,VASI 的最小平方平均分随着色素再沉着程度的增加而增加。PhGIC-V评分改善的患者与V-PhGIC评分无变化或恶化的患者之间的最小平方平均VASI评分也有所不同。使用多锚方法,T-VASI 和 F-VASI 评分分别提高了 30% 和 50%,这反映出在基线和第 24 周之间存在有意义的再色素沉着:这项混合方法研究发现,T-VASI 和 F-VASI 可靠、有效,能够区分临床上不同的群体,对非节段型白癜风患者反应灵敏。有意义变化的阈值低于临床试验中历来使用的阈值,表明T-VASI 50和F-VASI 75是保守的估计值,反映了对非节段性白癜风患者有意义的改善:试验注册:ClinicalTrials.gov Identifier:NCT04927975。
{"title":"Psychometric Properties and Meaningful Change Thresholds of the Vitiligo Area Scoring Index.","authors":"Khaled Ezzedine, Ahmed M Soliman, Heidi S Camp, Mary Kate Ladd, Robin Pokrzywinski, Karin S Coyne, Rohini Sen, Bethanee J Schlosser, Jung Min Bae, Iltefat Hamzavi","doi":"10.1001/jamadermatol.2024.4534","DOIUrl":"10.1001/jamadermatol.2024.4534","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Defining meaningful improvement using the Total Vitiligo Area Scoring Index (T-VASI) and the Facial VASI (F-VASI) aids interpretation of findings from clinical trials evaluating vitiligo treatments; however, clear and clinically meaningful thresholds have not yet been established.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To assess concept validity and measurement performance of the T-VASI and F-VASI in patients with nonsegmental vitiligo and to identify meaningful change thresholds.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, settings, and participants: &lt;/strong&gt;This mixed-methods study consisted of a secondary analysis of a phase 2 multicenter double-blind dose-ranging randomized clinical trial and embedded qualitative interviews conducted at 35 sites in Canada, France, Japan, and the US. The secondary analysis included the trial's adult patients with nonsegmental vitiligo (T-VASI ≥5 and F-VASI ≥0.5 at baseline). Psychometric performance of the T-VASI and F-VASI and thresholds for meaningful change were evaluated using clinician- and patient-reported information. The trial's embedded interviews were used to qualitatively assess content validity and patient perceptions of meaningful repigmentation. Data analyses were performed from March to July 2023.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Intervention: &lt;/strong&gt;Participants were randomized to 6-, 11-, or 22-mg/day upadacitinib or placebo for 24 weeks.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Psychometric performance of the T-VASI and F-VASI and thresholds for meaningful changed plus content validity and patient perceptions of meaningful repigmentation. Measurement instruments included the T-VASI, F-VASI, Vitiligo Noticeability Scale, Total-Patient Global Vitiligo Assessment, Face-Patient Global Vitiligo Assessment, Total-Physician Global Vitiligo Assessment (PhGVA-T), Face-Physician Global Vitiligo Assessment (PhGVA-F), Patient's Global Impression of Change-Vitiligo, Physician's Global Impression of Change-Vitiligo (PhGIC-V), Vitiligo Quality-of-Life Instrument, Dermatology Life Quality Index, the Hospital Anxiety and Depression Scale, and transcribed verbatim interviews with patients.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The psychometric analysis included 164 participants (mean [SD] age, 46 years; 103 [63%] females) and the qualitative analysis included 14 participants (mean [SD] age, 48.8 [12.2] years; 9 females [64%] and 5 males [36%]). Intraclass correlation coefficients were 0.98 for T-VASI and 0.99 for F-VASI in patients with clinically stable vitiligo between baseline and week 4, supporting test-retest reliability. At baseline and week 24, correlations were moderate to strong between T-VASI and PhGVA-T (r = 0.63-0.65) and between F-VASI and PhGVA-F (r = 0.65-0.71). Average baseline and week-24 VASI scores decreased with repigmentation (ie, increasing PhGVA scores). Least-square mean VASI scores increased with greater repigmentation as measured by the PhGIC-V. Least-square mean VASI scores also differed be","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"39-46"},"PeriodicalIF":11.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of Anti-PD1 Blockade After Hedgehog Inhibitors or as First-Line Therapy for Gorlin Syndrome. 在使用刺猬抑制剂后使用抗 PD1 阻断剂,或将其作为戈林综合征的一线疗法。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-01-01 DOI: 10.1001/jamadermatol.2024.4445
Robin Reschke, Jasmin Richter, Alexander H Enk, Jessica C Hassel
{"title":"Use of Anti-PD1 Blockade After Hedgehog Inhibitors or as First-Line Therapy for Gorlin Syndrome.","authors":"Robin Reschke, Jasmin Richter, Alexander H Enk, Jessica C Hassel","doi":"10.1001/jamadermatol.2024.4445","DOIUrl":"10.1001/jamadermatol.2024.4445","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"104-105"},"PeriodicalIF":11.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581658/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Skin Inflammation, Systemic Inflammation, and Cardiovascular Disease in Psoriasis. 牛皮癣的皮肤炎症、系统炎症和心血管疾病。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-01-01 DOI: 10.1001/jamadermatol.2024.4433
Axel Svedbom, Lotus Mallbris, Álvaro González-Cantero, Martin Playford, Colin Wu, Nehal N Mehta, Mona Ståhle

Importance: Psoriasis is associated with increased cardiovascular risk, but the underlying pathogenic mechanisms remain unclear. Elucidating these mechanisms can help develop treatment strategies and enhance understanding of the link between peripheral inflammation, such as psoriatic skin lesions, and cardiovascular disease (CVD).

Objective: To explore whether systemic inflammation is a mediator of the association between psoriasis skin disease severity and CVD.

Design, setting, and participants: This cohort study used data from cross-sectional study (Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative [PACI]), which enrolled patients from January 2013 to February 2022, and an inception cohort study (Stockholm Psoriasis Cohort [SPC]), which enrolled patients from January 2000 to December 2005. The PACI enrolled consecutive patients referred by dermatologists in Maryland, and the SPC enrolled consecutive patients referred from a wide range of practices in Sweden. Patients with prevalent psoriasis from the PACI and patients with incident psoriasis from the SPC were included. Data were analyzed from October 2023 to January 2024.

Exposures: Psoriasis skin disease severity was measured using the Psoriasis Area and Severity Index (PASI), and systemic inflammation was measured using glycan biomarker of N-acetyl side chains of acute-phase proteins (GlycA). Mediation analysis was performed by evaluating the associations between exposure, mediator, and outcome in patients with first-tertile and third-tertile PASI scores when GlycA level was set at the level observed in patients with first-tertile PASI.

Main outcomes and measures: Noncalcified coronary burden (NCB) measured using coronary computed tomography angiography in the PACI and hospitalization for CVD or cardiovascular death in the SPC.

Results: Of 260 eligible patients from the PACI, 162 (62.3%) were male, and the median (IQR) age was 51 (41-60) years; of 509 eligible patients from the SPC, 237 (46.6%) were male, and the median (IQR) age was 43 (30-57) years. In both studies, PASI was associated with GlycA level and CVD, and GlycA level was associated with CVD. The direct and indirect (through GlycA) effects of PASI on NCB were estimated at 0.94 (95% CI, 0.26-1.74) and 0.19 (95% CI, 0.02-0.47), respectively. The odds ratios for the direct and indirect effects of PASI on cardiovascular events were estimated at 1.23 (95% CI, 0.70-1.92) and 1.16 (95% CI, 1.04-1.42), respectively.

Conclusions and relevance: In this study, skin disease severity measured using PASI was associated with systemic inflammation, and both PASI and systemic inflammation, measured using GlycA levels, were associated with CVD. The association between PASI and CVD may be mediated by systemic inflammation.

重要性:银屑病与心血管风险增加有关,但其潜在的致病机制仍不清楚。阐明这些机制有助于制定治疗策略,并加深对银屑病皮损等外周炎症与心血管疾病(CVD)之间联系的理解:目的:探讨全身性炎症是否是银屑病皮损严重程度与心血管疾病之间关系的介导因素:这项队列研究使用了横断面研究(银屑病动脉粥样硬化和心脏代谢疾病倡议[PACI])和起始队列研究(斯德哥尔摩银屑病队列[SPC])的数据,前者从2013年1月至2022年2月招募患者,后者从2000年1月至2005年12月招募患者。PACI招募的是由马里兰州皮肤科医生转诊的连续患者,SPC招募的是由瑞典各医疗机构转诊的连续患者。PACI 中的银屑病流行期患者和 SPC 中的银屑病发病期患者均被纳入其中。数据分析时间为2023年10月至2024年1月:银屑病皮肤疾病严重程度采用银屑病面积和严重程度指数(PASI)进行测量,全身炎症采用急性期蛋白 N-乙酰侧链的聚糖生物标记物(GlycA)进行测量。当 GlycA 水平设定为 PASI 一档患者所观察到的水平时,通过评估 PASI 一档和三档患者的暴露、中介因子和结果之间的关联进行中介分析:在 PACI 中使用冠状动脉计算机断层扫描血管造影术测量非钙化冠状动脉负担(NCB),在 SPC 中测量心血管疾病住院或心血管疾病死亡:在PACI的260名合格患者中,162人(62.3%)为男性,年龄中位数(IQR)为51(41-60)岁;在SPC的509名合格患者中,237人(46.6%)为男性,年龄中位数(IQR)为43(30-57)岁。在这两项研究中,PASI 与 GlycA 水平和心血管疾病相关,而 GlycA 水平与心血管疾病相关。据估计,PASI 对 NCB 的直接和间接(通过 GlycA)影响分别为 0.94(95% CI,0.26-1.74)和 0.19(95% CI,0.02-0.47)。PASI对心血管事件的直接和间接影响的几率估计分别为1.23(95% CI,0.70-1.92)和1.16(95% CI,1.04-1.42):在这项研究中,使用 PASI 测量的皮肤病严重程度与全身炎症相关,而使用 GlycA 水平测量的 PASI 和全身炎症与心血管疾病相关。PASI与心血管疾病之间的关联可能是由全身炎症介导的。
{"title":"Skin Inflammation, Systemic Inflammation, and Cardiovascular Disease in Psoriasis.","authors":"Axel Svedbom, Lotus Mallbris, Álvaro González-Cantero, Martin Playford, Colin Wu, Nehal N Mehta, Mona Ståhle","doi":"10.1001/jamadermatol.2024.4433","DOIUrl":"10.1001/jamadermatol.2024.4433","url":null,"abstract":"<p><strong>Importance: </strong>Psoriasis is associated with increased cardiovascular risk, but the underlying pathogenic mechanisms remain unclear. Elucidating these mechanisms can help develop treatment strategies and enhance understanding of the link between peripheral inflammation, such as psoriatic skin lesions, and cardiovascular disease (CVD).</p><p><strong>Objective: </strong>To explore whether systemic inflammation is a mediator of the association between psoriasis skin disease severity and CVD.</p><p><strong>Design, setting, and participants: </strong>This cohort study used data from cross-sectional study (Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative [PACI]), which enrolled patients from January 2013 to February 2022, and an inception cohort study (Stockholm Psoriasis Cohort [SPC]), which enrolled patients from January 2000 to December 2005. The PACI enrolled consecutive patients referred by dermatologists in Maryland, and the SPC enrolled consecutive patients referred from a wide range of practices in Sweden. Patients with prevalent psoriasis from the PACI and patients with incident psoriasis from the SPC were included. Data were analyzed from October 2023 to January 2024.</p><p><strong>Exposures: </strong>Psoriasis skin disease severity was measured using the Psoriasis Area and Severity Index (PASI), and systemic inflammation was measured using glycan biomarker of N-acetyl side chains of acute-phase proteins (GlycA). Mediation analysis was performed by evaluating the associations between exposure, mediator, and outcome in patients with first-tertile and third-tertile PASI scores when GlycA level was set at the level observed in patients with first-tertile PASI.</p><p><strong>Main outcomes and measures: </strong>Noncalcified coronary burden (NCB) measured using coronary computed tomography angiography in the PACI and hospitalization for CVD or cardiovascular death in the SPC.</p><p><strong>Results: </strong>Of 260 eligible patients from the PACI, 162 (62.3%) were male, and the median (IQR) age was 51 (41-60) years; of 509 eligible patients from the SPC, 237 (46.6%) were male, and the median (IQR) age was 43 (30-57) years. In both studies, PASI was associated with GlycA level and CVD, and GlycA level was associated with CVD. The direct and indirect (through GlycA) effects of PASI on NCB were estimated at 0.94 (95% CI, 0.26-1.74) and 0.19 (95% CI, 0.02-0.47), respectively. The odds ratios for the direct and indirect effects of PASI on cardiovascular events were estimated at 1.23 (95% CI, 0.70-1.92) and 1.16 (95% CI, 1.04-1.42), respectively.</p><p><strong>Conclusions and relevance: </strong>In this study, skin disease severity measured using PASI was associated with systemic inflammation, and both PASI and systemic inflammation, measured using GlycA levels, were associated with CVD. The association between PASI and CVD may be mediated by systemic inflammation.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"81-86"},"PeriodicalIF":11.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11579891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Palmar Fasciitis and Polyarthritis Syndrome.
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-01-01 DOI: 10.1001/jamadermatol.2024.5015
Xiao Ma, Dong-Lai Ma
{"title":"Palmar Fasciitis and Polyarthritis Syndrome.","authors":"Xiao Ma, Dong-Lai Ma","doi":"10.1001/jamadermatol.2024.5015","DOIUrl":"10.1001/jamadermatol.2024.5015","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"98-99"},"PeriodicalIF":11.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials. Deucravacitinib 对中度至重度斑块状银屑病长达 3 年的安全性和疗效:随机临床试验的开放标签延伸。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-01-01 DOI: 10.1001/jamadermatol.2024.4688
April W Armstrong, Mark Lebwohl, Richard B Warren, Howard Sofen, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim A Papp, Renata M Kisa, John Vaile, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J Colombo, Julie Scotto, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt
<p><strong>Importance: </strong>Safe and effective long-term treatments for moderate to severe plaque psoriasis are needed.</p><p><strong>Objective: </strong>To evaluate the long-term safety and efficacy of deucravacitinib through 3 years (week 148) in the randomized POETYK PSO-1, PSO-2, and nonrandomized long-term extension (LTE) trials.</p><p><strong>Design, setting, and participants: </strong>PSO-1/PSO-2 were global, 52-week, randomized, double-blinded phase 3 trials in patients with moderate to severe plaque psoriasis. After completing 52 weeks of treatment in PSO-1/PSO-2, patients could enroll in the prespecified, ongoing, nonrandomized LTE trial. The peak of the global COVID-19 pandemic coincided with the LTE trial. Patient enrollment in the LTE started August 12, 2019; safety and efficacy were assessed through June 15, 2022; and these data were analyzed through June 28, 2024.</p><p><strong>Interventions: </strong>The PSO-1/PSO-2 trials randomized patients 1:2:1 to oral placebo, deucravacitinib, 6 mg once daily, or apremilast, 30 mg twice daily. Patients enrolling in the LTE trial received open-label deucravacitinib, 6 mg once daily.</p><p><strong>Main outcomes and measures: </strong>Safety outcomes were evaluated in patients who received 1 or more doses of deucravacitinib. Efficacy outcomes included 75% or greater or 90% or greater reduction from baseline in Psoriasis Area and Severity Index (PASI 75/90) and static Physician Global Assessment scores of 0 (clear) or 1 (almost clear) (sPGA 0/1) and were assessed in patients who received deucravacitinib treatment from day 1 of the parent trials who continued in the LTE trial.</p><p><strong>Results: </strong>Of 1519 patients who received 1 or more doses of deucravacitinib, 513 received continuous deucravacitinib treatment from day 1 and entered the LTE trial. Exposure-adjusted incidence rates (EAIRs) per 100 person-years were decreased or similar in the 1-year vs 3-year cumulative periods, respectively, for adverse events (AEs) (229.2 vs 144.8; 95% CI, 215.4-243.9 vs 137.1-153.0), serious AEs (5.7 vs 5.5; 95% CI, 4.4-7.4 vs 4.7-6.4), discontinuations due to AEs (4.4 vs 2.4; 95% CI, 3.3-5.9 vs 2.0-3.0), and deaths (0.2 vs 0.3; 95% CI, 0.1-0.8 vs 0.2-0.6). Incidence rates of the most common AEs (EAIR per 100 person-years ≥5) during the 1-year and 3-year cumulative periods, respectively, were nasopharyngitis (26.1 vs 11.4; 95% CI, 23.0-29.8 vs 10.2-12.7), COVID-19 (0.5 vs 8.0; 95% CI, 0.2-1.2 vs 7.1-9.1), and upper respiratory tract infection (13.4 vs 6.2; 95% CI, 11.3-16.0 vs 5.4-7.2). EAIRs for AEs of interest, including herpes zoster, major adverse cardiovascular events, and malignant diseases, remained low and were decreased or comparable between the 1-year and 3-year cumulative periods. Clinical response rates were maintained through 3 years.</p><p><strong>Conclusions and relevance: </strong>The findings of this integrated analysis of the phase 3 POETYK PSO-1, PSO-2, and nonrandomized LTE tr
重要性:中重度斑块状银屑病需要安全有效的长期治疗方法:在随机 POETYK PSO-1、PSO-2 和非随机长期扩展(LTE)试验中,评估 deucravacitinib 长达 3 年(第 148 周)的长期安全性和疗效:PSO-1/PSO-2是针对中度至重度斑块状银屑病患者的全球性、为期52周的随机双盲3期试验。在完成PSO-1/PSO-2为期52周的治疗后,患者可参加预设的、正在进行的非随机LTE试验。全球 COVID-19 大流行的高峰期正好与 LTE 试验同时进行。LTE试验的患者注册从2019年8月12日开始;安全性和有效性评估持续到2022年6月15日;这些数据的分析持续到2024年6月28日:PSO-1/PSO-2试验以1:2:1的比例将患者随机分配到口服安慰剂、每天一次每次6毫克的deucravacitinib或每天两次每次30毫克的apremilast。参加LTE试验的患者接受开放标签的德拉瓦替尼治疗,每天一次,每次6毫克:主要结果和指标:对接受1次或1次以上剂量德拉瓦替尼治疗的患者进行安全性评价。疗效结果包括银屑病面积和严重程度指数(PASI 75/90)比基线降低75%或以上或90%或以上,以及静态医生总体评估评分为0(清晰)或1(基本清晰)(sPGA 0/1),评估对象为从母体试验第1天开始接受德拉瓦替尼治疗并继续参加LTE试验的患者:在接受了1次或1次以上剂量德拉瓦替尼治疗的1519名患者中,有513名患者从第1天开始持续接受德拉瓦替尼治疗,并参加了LTE试验。在不良事件(AEs)方面,每百人年暴露调整发病率(EAIRs)在1年和3年的累积期分别下降或相似(229.2 vs 144.8; 95% CI, 215.4-243.9 vs 137.1-153.0)、严重不良事件(5.7 vs 5.5;95% CI,4.4-7.4 vs 4.7-6.4)、不良事件导致的停药(4.4 vs 2.4;95% CI,3.3-5.9 vs 2.0-3.0)和死亡(0.2 vs 0.3;95% CI,0.1-0.8 vs 0.2-0.6)。最常见的 AEs(每百人年 EAIR ≥5)在 1 年和 3 年累计期间的发病率分别为鼻咽炎(26.1 vs 11. 4;95% CI,23.0-3.0)和死亡(0.2 vs 0.3;95% CI,0.1-0.8 vs 0.2-0.6)。4;95% CI,23.0-29.8 vs 10.2-12.7)、COVID-19(0.5 vs 8.0;95% CI,0.2-1.2 vs 7.1-9.1)和上呼吸道感染(13.4 vs 6.2;95% CI,11.3-16.0 vs 5.4-7.2)。包括带状疱疹、主要不良心血管事件和恶性疾病在内的相关 AE 的 EAIR 仍保持在较低水平,且在 1 年和 3 年累积期之间有所下降或不相上下。临床应答率保持了 3 年:这项对 POETYK PSO-1、PSO-2 和非随机 LTE 试验的 3 期综合分析结果表明,银屑病患者持续使用 deucravacitinib 治疗 3 年,具有一致的安全性和持久的临床应答:试验注册:ClinicalTrials.gov Identifiers:NCT03624127、NCT03611751和NCT04036435。
{"title":"Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.","authors":"April W Armstrong, Mark Lebwohl, Richard B Warren, Howard Sofen, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim A Papp, Renata M Kisa, John Vaile, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J Colombo, Julie Scotto, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt","doi":"10.1001/jamadermatol.2024.4688","DOIUrl":"10.1001/jamadermatol.2024.4688","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Safe and effective long-term treatments for moderate to severe plaque psoriasis are needed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To evaluate the long-term safety and efficacy of deucravacitinib through 3 years (week 148) in the randomized POETYK PSO-1, PSO-2, and nonrandomized long-term extension (LTE) trials.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;PSO-1/PSO-2 were global, 52-week, randomized, double-blinded phase 3 trials in patients with moderate to severe plaque psoriasis. After completing 52 weeks of treatment in PSO-1/PSO-2, patients could enroll in the prespecified, ongoing, nonrandomized LTE trial. The peak of the global COVID-19 pandemic coincided with the LTE trial. Patient enrollment in the LTE started August 12, 2019; safety and efficacy were assessed through June 15, 2022; and these data were analyzed through June 28, 2024.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interventions: &lt;/strong&gt;The PSO-1/PSO-2 trials randomized patients 1:2:1 to oral placebo, deucravacitinib, 6 mg once daily, or apremilast, 30 mg twice daily. Patients enrolling in the LTE trial received open-label deucravacitinib, 6 mg once daily.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Safety outcomes were evaluated in patients who received 1 or more doses of deucravacitinib. Efficacy outcomes included 75% or greater or 90% or greater reduction from baseline in Psoriasis Area and Severity Index (PASI 75/90) and static Physician Global Assessment scores of 0 (clear) or 1 (almost clear) (sPGA 0/1) and were assessed in patients who received deucravacitinib treatment from day 1 of the parent trials who continued in the LTE trial.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Of 1519 patients who received 1 or more doses of deucravacitinib, 513 received continuous deucravacitinib treatment from day 1 and entered the LTE trial. Exposure-adjusted incidence rates (EAIRs) per 100 person-years were decreased or similar in the 1-year vs 3-year cumulative periods, respectively, for adverse events (AEs) (229.2 vs 144.8; 95% CI, 215.4-243.9 vs 137.1-153.0), serious AEs (5.7 vs 5.5; 95% CI, 4.4-7.4 vs 4.7-6.4), discontinuations due to AEs (4.4 vs 2.4; 95% CI, 3.3-5.9 vs 2.0-3.0), and deaths (0.2 vs 0.3; 95% CI, 0.1-0.8 vs 0.2-0.6). Incidence rates of the most common AEs (EAIR per 100 person-years ≥5) during the 1-year and 3-year cumulative periods, respectively, were nasopharyngitis (26.1 vs 11.4; 95% CI, 23.0-29.8 vs 10.2-12.7), COVID-19 (0.5 vs 8.0; 95% CI, 0.2-1.2 vs 7.1-9.1), and upper respiratory tract infection (13.4 vs 6.2; 95% CI, 11.3-16.0 vs 5.4-7.2). EAIRs for AEs of interest, including herpes zoster, major adverse cardiovascular events, and malignant diseases, remained low and were decreased or comparable between the 1-year and 3-year cumulative periods. Clinical response rates were maintained through 3 years.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;The findings of this integrated analysis of the phase 3 POETYK PSO-1, PSO-2, and nonrandomized LTE tr","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"56-66"},"PeriodicalIF":11.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultraprocessed Food Intake and Psoriasis. 超加工食品摄入量与牛皮癣。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-01-01 DOI: 10.1001/jamadermatol.2024.4832
Laetitia Penso, Mathilde Touvier, Bernard Srour, Khaled Ezzedine, Emilie Sbidian
{"title":"Ultraprocessed Food Intake and Psoriasis.","authors":"Laetitia Penso, Mathilde Touvier, Bernard Srour, Khaled Ezzedine, Emilie Sbidian","doi":"10.1001/jamadermatol.2024.4832","DOIUrl":"10.1001/jamadermatol.2024.4832","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"105-108"},"PeriodicalIF":11.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Annular Eroded Plaque With Honey-Colored Crusting On Scrotum. 阴囊上有环状蚀斑,并伴有蜜色结痂。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-01-01 DOI: 10.1001/jamadermatol.2024.4424
Toan S Bui, Jonathan J Lee
{"title":"Annular Eroded Plaque With Honey-Colored Crusting On Scrotum.","authors":"Toan S Bui, Jonathan J Lee","doi":"10.1001/jamadermatol.2024.4424","DOIUrl":"10.1001/jamadermatol.2024.4424","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"100-101"},"PeriodicalIF":11.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JAMA dermatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1